Skip to main content
Bodoky_Gyorgy_Vastagbeldaganat

 

Irodalom:
1. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H,
Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P.: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb
10;27(5):663-71.
2. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B,
Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W: Adding cetuximab to
capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized
phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Swiss Group for Clinical Cancer
Research (SAKK), Bern, Switzerland. Ann Oncol. 2008 Jul;19(7):1288-92.
3. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A,
Langer C, Kopit J, Burris HA 3rd.: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine
and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May
10;26(14):2311-9.
4. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH,
Siena S.: Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on
irinotecan: MABEL Study. J Clin Oncol. 2008 Nov 20;26(33):5335-43.
5. Tsai HL, Chang YT, Chu KS, Chen CF, Yeh YS, Ma CJ, Wu DC, Kuo CH, Chan HM, Sheen MC, Wang JY.:
Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in
patients with metastatic colorectal cancer. Int J Biol Markers. 2008 Oct-Dec;23(4):244-8.
6. Neyns B, Aerts M, Van Nieuwenhove Y, Fontaine C, De Coster L, Schallier D, Vanderauwera J,
De Munck F, Vandenbroucke F, Everaert H, Meert V, De Mey J, De Ridder M, Delvaux G, De Greve J.:
Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver
metastases. Anticancer Res. 2008 Jul-Aug;28(4C):2459-67.
7. Annemans L, Van Cutsem E, Humblet Y, Van Laethem JL, Bleiberg H.: Cost-effectiveness of cetuximab
in combination with irinotecan compared with current care in metastatic colorectal cancer after failure
on irinotecan–a Belgian analysis. Acta Clin Belg. 2007 Nov-Dec;62(6):419-25.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R,
Patterson SD, Chang DD.: Wild-type KRAS is required for panitumumab efficacy in patients with
metastatic colorectal cancer. J Clin Oncol. 2008 Apr 1;26(10):1626-34.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H,
Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.: K-ras mutations
and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65.
10. Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P,
Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G.: K-Ras mutations and
treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer
Res. 2008 Aug 1;14(15):4830-5.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 227
228 Gastro Update 2009
11. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O.: The clinical benefit of bevacizumab in metastatic
colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab
with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009 Jan;14(1):22-8.
12. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M.: Bevacizumab beyond
first progression is associated with prolonged overall survival in metastatic colorectal cancer: results
from a large observational cohort study (BRiTE). J Clin Oncol. 2008 Nov 20;26(33):5326-34.
13. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, Couture F, Sirzén F, Cassidy J.: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin
Oncol. 2008 Apr 20;26(12):2013-9. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol.
2009 Feb 1;27(4):653.
14. Kabbinavar F, Irl C, Zurlo A, Hurwitz H.: Bevacizumab improves the overall and progression-free survival
of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of
baseline risk. Oncology. 2008;75(3-4):215-23.
15. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O.: Addition of bevacizumab to fluorouracil-based
first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two
randomized clinical trials. J Clin Oncol. 2009 Jan 10;27(2):199-205.
16. Bege T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D, Moureau-Zabotto L, Giovannini M,
Gonçalves A, Delpero JR.: Bevacizumab-Related Surgical Site Complication Despite Primary Tumor
Resection in Colorectal Cancer Patients. Ann Surg Oncol. 2009 Jan 21.
17. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D,
Stella P, Deeter R, Shahin S, Amado RG.: A randomized phase IIIB trial of chemotherapy, bevacizumab,
and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
J Clin Oncol. 2009 Feb 10;27(5):672-80.
18. C. J. Punt, J. Tol, C. J. Rodenburg, A. Cats, G. Creemers, J. G. Schrama, F. L. Erdkamp, A. Vos, L. Mol,
N. F. Antonini: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without
cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer
Group (DCCG). J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA4011).
19. Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P,
Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM.: Pooled Safety and Efficacy Analysis
Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using
Individual Data From Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2009 Mar 2.
20. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, Couture F, Sirzén F, Saltz L.: Randomized phase III study of capecitabine plus oxaliplatin
compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal
cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12.
21. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D.:
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4)
as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann
Oncol. 2008 Oct;19(10):1720-6.
22. Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, Carrato A, Reina JJ, Queralt B,
Gómez-Espana A, González-Flores E, Rivera F, Losa F, García T, Sanchez-Rovira P, Maestu I, DíazRubio
E.: Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity
after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-
TTD-01 phase III study. Crit Rev Oncol Hematol. 2008 Dec 24.
23. Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH Jr, Bodoky G, Habboubi N, Garay C,
Olivatto LO.: Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after
Gastro 2009.qxd 5/9/2009 1:41 PM Page 228
A vastagbél 229
single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008 Oct
1;26(28):4544-50.
24. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR,
Park CH, Kim KO, Kim MJ, Jang KM.: Phase II study with oxaliplatin and S-1 for patients with
metastatic colorectal cancer. Ann Oncol. 2009 Jan 19.
25. Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G, Bengrine-Lefevre L,
Maindrault-Goebel F, Louvet C, de Gramont A.: Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined
with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer
in the GERCOR OPTIMOX1 study. Ann Oncol. 2009 Jan 19.
26. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M;
on behalf of the European Colorectal Metastases Treatment Group.: Combination of surgery and
chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases:
recommendations from an expert panel. Ann Oncol. 2009 Jan 19.
27. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN,
Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E,
Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK;
Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie
(ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de
Cancérologie Digestive (FFCD).: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery
alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a
randomised controlled trial. Lancet. 2008 Mar 22;371(9617):1007-16.
28. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F,
Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A.: Long-term outcome of
initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin,
and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009 Mar;249(3):420-5.
29. Tamandl D, Gruenberger B, Herberger B, Kaczirek K, Gruenberger T.: Surgery after neoadjuvant
chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol. 2009 Feb 20.
30. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T.: Bevacizumab,
capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic
colorectal cancer. J Clin Oncol. 2008 Apr 10;26(11):1830-5.
31. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C,
Gruenberger B, Gruenberger T.: Bevacizumab protects against sinusoidal obstruction syndrome and
does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver
metastases. Eur J Surg Oncol. 2009 Feb 4.
32. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O’Callaghan C,
Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P.:
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a
pooled analysis of two randomized trials. J Clin Oncol. 2008 Oct 20;26(30):4906-11.
Ajánlott irodalom
K-ras
1. Weber J, McCormack PL.: Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
BioDrugs. 2008;22(6):403-11. doi: 10.2165/0063030-200822060-00006.
2. Ramos FJ, Macarulla T, Capdevila J, Elez E, Tabernero J.: Understanding the predictive role of K-ras
for epidermal growth factor receptor-targeted therapies in colorectal cancer. Clin Colorectal Cancer.
2008 Dec;7 Suppl 2:S52-7.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 229
230 Gastro Update 2009
3. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato
Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G,
Ensari A.: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma:
proposal for an European quality assurance program. Virchows Arch. 2008 Nov;453(5):417-31.
4. Garcia J, Riely GJ, Nafa K, Ladanyi M.: KRAS mutational testing in the selection of patients for
EGFR-targeted therapies. Semin Diagn Pathol. 2008 Nov;25(4):288-94.
5. Codacci-Pisanelli G, Spinelli G, Tomao S.: K-ras mutations and cetuximab in colorectal cancer. N Engl
J Med. 2009 Feb 19;360(8):835; author reply 835-6.
6. De Roock W, Lambrechts D, Tejpar S.: K-ras mutations and cetuximab in colorectal cancer. N Engl J
Med. 2009 Feb 19;360(8):834; author reply 835-6.
7. de Reynies A, Boige V, Milano G, Faivre J, Laurent-Puig P.: KRAS mutation signature in colorectal
tumors significantly overlaps with the cetuximab response signature. J Clin Oncol. 2008 May
1;26(13):2228-30; author reply 2230-1.
8. Eng C.: K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. Clin Adv Hematol
Oncol. 2008 Mar;6(3):174-5.
9. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, Bardelli A.: Wild-type BRAF is required for response to panitumumab or cetuximab
in metastatic colorectal cancer. J Clin Oncol. 2008 Dec 10;26(35):5705-12.
Célzott terápia
1. Langerak A, River G, Mitchell E, Cheema P, Shing M.: Panitumumab monotherapy in patients with
metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin
Colorectal Cancer. 2009 Jan;8(1):49-54.
2. Cercek A, Saltz LB.: First-line treatment of patients with metastatic colorectal cancer: an overview of
recent data on chemotherapy plus targeted agents. Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S47-51.
3. Chu E.: Recent developments on the integration of biologic agents with cytotoxic chemotherapy in the
treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S46.
4. Rödel C, Höhler T, Sauer R, Siewczynski R, Flentje M, Budach V, Schlag PM.: Multimodality treatment
for colorectal cancer]. Onkologie. 2008;31 Suppl 5:24-8.
5. Overman M, Kopetz S.: Picking the right road for metastatic colorectal cancer patients. Oncology
(Williston Park). 2008 Nov 30;22(13):1482-3.
6. Turja J, Grothey A.: Individualizing therapy for metastatic colorectal cancer. Oncology (Williston
Park). 2008 Nov 30;22(13):1479-81.
7. Acoba JD.: Individualizing colon cancer treatment: the role of predictive and prognostic factors.
Hawaii Med J. 2008 Nov;67(11):304-6.
8. Ellis LM, Haller DG.: Bevacizumab beyond progression: does this make sense? J Clin Oncol. 2008
Nov 20;26(33):5313-5.
9. Davies JM, Goldberg RM.: First-line therapeutic strategies in metastatic colorectal cancer. Oncology
(Williston Park). 2008 Nov 30;22(13):1470-9.
10. Booth C.: Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm. J Clin
Oncol. 2008 Oct 1;26(28):4693-4; author reply 4694-5. No abstract available.
11. Chu E.: Sequential versus combination therapy: where are we? Clin Colorectal Cancer. 2008
Sep;7(5):295.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 230
A vastagbél 231
12. Bilchik AJ, Hecht JR.: Perioperative risks of bevacizumab and other biologic agents for hepatectomy:
theoretical or evidence based? J Clin Oncol. 2008 Apr 10;26(11):1786-8.
13. Yang F, Fu D, Ni Q.: Cetuximab for colorectal cancer. N Engl J Med. 2008 Mar 13;358(11):1195;
author reply 1196-7.
14. Ciardiello F, Tortora G.: EGFR antagonists in cancer treatment. N Engl J Med. 2008 Mar
13;358(11):1160-74. Review.
15. Blanke CD.: Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may. J
Clin Oncol. 2009 Feb 10;27(5):655-8. Epub 2008 Dec 29.
16. Edna TH, Jullumströ E, Lydersen S.: Chemotherapy for nonresectable colorectal cancer at a center during
25 years. Hepatogastroenterology. 2008 Nov-Dec;55(88):2049-53.
17. Zhang YJ, Zhao SL, Tian XQ, Sun DF, Xiong H, Dai Q, Li XQ, Fang JY.: Combined inhibition of Dnmt
and mTOR signaling inhibits formation and growth of colorectal cancer. Int J Colorectal Dis. 2009 Feb 20.
18. Mayer RJ.: Targeted therapy for advanced colorectal cancer–more is not always better. N Engl J Med.
2009 Feb 5;360(6):623-5.
19. Windsor AC, Cohen R, Jiao LR, Stebbing J.: Cetuximab in the first-line therapy of metastatic colorectal
carcinoma: not so CRYSTAL clear. Future Oncol. 2008 Dec;4(6):741-4.
20. Grothey A, Ellis LM.: Targeting angiogenesis driven by vascular endothelial growth factors using
antibody-based therapies. Cancer J. 2008 May-Jun;14(3):170-7.
21. Loupakis F, Masi G, Vasile E, Falcone A.: First-line chemotherapy in metastatic colorectal cancer: new
approaches and therapeutic algorithms. Always hit hard first? Curr Opin Oncol. 2008 Jul;20(4):459-65.
22. Simkens L, Tol J, Koopman M, Mol L, Antonini N, van Krieken H, Punt C.: Current questions in the
treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
Clin Colorectal Cancer. 2008 Mar;7(2):105-9.
23. Lenz HJ.: First-line combination treatment of colorectal cancer with hepatic metastases: choosing a
targeted agent. Cancer Treat Rev. 2008;34 Suppl 2:S3-7.
24. Van Buren G 2nd, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ,
Ellis LM.: Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol. 2008
Apr 10;26(11):1836-42.
25. Punt CJ, Koopman M.: Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
J Clin Oncol. 2008 Apr 10;26(11):1907-8; author reply 1908-9.
26. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A.:
Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.
J Clin Oncol. 2008 Mar 1;26(7):1188-9; author reply 1189-90.
27. Grothey A, Sargent DJ.: New lessons from “old” chemotherapy in colorectal cancer. J Clin Oncol. 2008
Oct 1;26(28):4532-4.
28. Ananda S, Field KM, Kosmider S, Compston D, Desai J, Lim LC, Barnett FS, Jones IT, Skinner I, Gibbs P.:
Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon
cancer in routine clinical practice. J Clin Oncol. 2008 Sep 20;26(27):4516-7; author reply 4517-8.
29. Petrelli NJ.: Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin
Oncol. 2008 Oct 20;26(30):4862-3. Epub 2008 Sep 15.
30. Sharma RA, Wasan HS, Love SB, Dutton S, Stokes JC, Smith JL; FOXFIRE Trial Management Group.:
FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases
in patients with colorectal cancer. Clin Oncol (R Coll Radiol). 2008 Apr;20(3):261-3.
Gastro 2009.qxd 5/9/2009 1:41 PM Page 231
232 Gastro Update 2009
31. Cassidy J, Schmoll HJ, Van Cutsem E.: Should capecitabine replace infusional fluorouracil and leucovorin
when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol. 2008 May 1;26(13):
2226-7; author reply 2228.
32. Chun YS, Laurent A, Maru D, Vauthey JN.: Management of chemotherapy-associated hepatotoxicity in
colorectal liver metastases. Lancet Oncol. 2009 Mar;10(3):278-86.

Leave a Reply

Close Menu

Kapcsolatfelvétel

Munkatársaink szívesen állnak rendelkezésre alábbi elérhetőségeinken: